Spruce Street Capital LP Invests $11.99 Billion in InflaRx N.V. $IFRX

Spruce Street Capital LP acquired a new stake in shares of InflaRx N.V. (NASDAQ:IFRX) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 5,352,198 shares of the company’s stock, valued at approximately $11,988,924,000. InflaRx accounts for about 2.4% of Spruce Street Capital LP’s portfolio, making the stock its 13th largest holding. Spruce Street Capital LP owned about 3.63% of InflaRx as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sanctuary Advisors LLC bought a new position in InflaRx in the 2nd quarter worth $25,000. Cubist Systematic Strategies LLC increased its position in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares in the last quarter. HRT Financial LP purchased a new stake in InflaRx in the fourth quarter worth about $47,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after buying an additional 19,200 shares in the last quarter. Finally, Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the fourth quarter worth about $61,000. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Zacks Research raised InflaRx from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 27th. HC Wainwright increased their target price on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Cantor Fitzgerald raised their target price on shares of InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and upped their price target for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

InflaRx Stock Down 2.4%

Shares of InflaRx stock opened at $2.05 on Tuesday. The company has a market capitalization of $302.11 million, a price-to-earnings ratio of -3.53 and a beta of 2.48. The stock’s 50-day simple moving average is $1.94 and its 200-day simple moving average is $1.62. InflaRx N.V. has a 52 week low of $0.80 and a 52 week high of $2.95.

InflaRx (NASDAQ:IFRX) last released its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, equities analysts expect that InflaRx N.V. will post -0.31 earnings per share for the current year.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.